Neurocrine Biosciences (NASDAQ:NBIX) Issues Quarterly Earnings Results, Misses Estimates By $0.62 EPS

Neurocrine Biosciences (NASDAQ:NBIX) announced its quarterly earnings data on Thursday. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62), Zacks reports. Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded down $0.69 during trading on Thursday, hitting $150.51. 1,239,814 shares of the company were exchanged, compared to its average volume of 965,840. The firm has a market capitalization of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33. The firm’s fifty day moving average price is $138.41 and its 200 day moving average price is $131.64. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NBIX shares. Barclays boosted their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 23rd. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. BMO Capital Markets cut their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $166.85.

Insider Activity at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 623 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the transaction, the insider now owns 3,442 shares in the company, valued at $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kyle Gano sold 65,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,693 shares of company stock worth $32,718,279. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.